Mepolizumab

Alternative Names: Nucala

Mepolizumab (Nucala) is a biologic medication injected used to treat severe eosinophilic asthma. It is a monoclonal antibody that targets interleukin-5 (IL-5), a key cytokine responsible for the growth and survival of eosinophils, which play a significant role in airway inflammation in eosinophilic asthma. Approved for patients ≥6 years old with severe eosinophilic asthma that is not well-controlled with standard inhalers (e.g., corticosteroids, long-acting beta-agonists).

Treatment Type: N/A

Treatment Class: Il-5 antagonist

Treatment Modality: Injection

Mepolizumab

Review Summary

4.0

1 Reviews

Preferred by 1 Reviewers

Based on the single expert review, Mepolizumab appears to be an effective add-on treatment for severe eosinophilic asthma when other standard therapies fail to control symptoms adequately. It works by targeting IL-5 to reduce eosinophil-driven inflammation, resulting in fewer exacerbations, improved lung function, and potentially decreased reliance on oral steroids.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
4.0
1 = Very Expensive 5 = Very Affordable

4.0

Affordable
Relief Speed
3.0
1 = No Relief 5 = Immediate Relief

3.0

Moderate Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
1.0
1 = Third-line or more 5 = First-line

1.0

Third-line or more

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

4.0

1 Reviews
5
0%
4
100%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the single expert review, Mepolizumab appears to be an effective add-on treatment for severe eosinophilic asthma when other standard therapies fail to control symptoms adequately. It works by targeting IL-5 to reduce eosinophil-driven inflammation, resulting in fewer exacerbations, improved lung function, and potentially decreased reliance on oral steroids.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
5 months ago
Mepolizumab is an add-on treatment for severe eosinophilic asthma, used when high-dose inhaled corticosteroids and other controllers fail to control symptoms. It reduces exacerbations, improves lung function, and may decrease oral steroid dependence by targeting IL-5 to lower eosinophil-driven inflammation.
#Affordable #CoveredByInsurance #ModerateRelief #MildEffect #Third-lineOrMore #Maintenance
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All